ARVN Earnings Date: Nov 3, 2026 (Estimated) — Arvinas, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ARVN's next earnings date?
Arvinas, Inc. (ARVN) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.87 on revenue of $16.8M.
How did ARVN do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Arvinas, Inc. posted EPS of $2.58 versus the -$0.37 estimate, a beat of 1092.3%. Revenue was $249.7M against a $60.7M estimate. The stock's 1-day post-earnings move was +11.7%.
How much does ARVN stock move after earnings?
ARVN beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.6% (up or down) in the day after earnings.
About Arvinas, Inc.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -0.37 | 2.58 | +1092.31% | $249.7M | ✅ Beat | +11.66% | +11.54% | +15.14% |
| 2026-05-12 | Q1 2026 | -0.96 | -0.90 | +6.25% | $15.6M | ✅ Beat | -0.93% | -9.11% | -27.74% |
| 2026-02-24 | Q4 2025 | -0.56 | -1.10 | -96.43% | $9.5M | ❌ Miss | +0.57% | +8.86% | -16.34% |
| 2025-11-05 | Q3 2025 | -0.75 | -0.48 | +36.00% | $41.9M | ✅ Beat | +0.31% | +17.51% | +31.55% |
| 2025-08-06 | Q2 2025 | -0.88 | -0.84 | +4.55% | $22.4M | ✅ Beat | -15.51% | -10.78% | +0.00% |
| 2025-02-11 | Q4 2024 | -0.96 | -0.63 | +34.38% | $59.2M | ✅ Beat | -6.80% | -1.69% | -52.40% |
| 2024-07-30 | Q2 2024 | -0.86 | -0.49 | +43.02% | $76.5M | ✅ Beat | -2.48% | -10.30% | -7.27% |
| 2024-05-07 | Q1 2024 | -1.42 | -0.97 | +31.69% | $25.3M | ✅ Beat | +6.42% | -2.14% | -13.42% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $246.2M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Collaboration Agreement Revenue | 54.3% | $133.7M | — | — | — | — | — |
| License | 25.4% | $62.5M | -51.9% | $130.0M | $130.0M | $130.0M | $130.0M |
| Milestone Revenue | 20.3% | $50.0M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.